Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinazolinone, quinolone and related analogs as sirtuin modulators

A compound and unsaturated technology, applied in the direction of drug combination, medical preparations containing active ingredients, metabolic diseases, etc., can solve the problems of reducing and prolonging the life span of wild-type cells

Inactive Publication Date: 2015-06-24
SIRTRIS PHARMA INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, mutations that reduce the activity of the yeast glucose-responsive cAMP (adenosine 3′,5′-monophosphate)-dependent (PKA) pathway extend lifespan in wild-type cells but not in mutant sir2 strains extension, which demonstrates that SIR2 may be a key downstream component of the caloric restriction pathway

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinazolinone, quinolone and related analogs as sirtuin modulators
  • Quinazolinone, quinolone and related analogs as sirtuin modulators
  • Quinazolinone, quinolone and related analogs as sirtuin modulators

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0334] Example 1. N-(3-methyl-4-oxo-2-(3-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-8-yl) Synthesis of pyridine-2-carboxamide (compound 239):

[0335] Step 1. 8-Nitro-2-(3-(trifluoromethyl)phenyl)-4H-benzo[d][1,3] Preparation of oxazin-4-one (3):

[0336]

[0337] 3-(Trifluoromethyl)benzoyl chloride 2 (4.5 mL, 30.2 mmol) was added to a suspension of 2-amino-3-nitrobenzoic acid 1 (5.0 g, 27.5 mmol) in pyridine (65 mL). The reaction mixture was stirred at room temperature for 12 h, then poured into ice-cooled H 2 O (300mL). The resulting precipitate was collected by filtration and washed with H 2 O washed and dried in vacuo to afford 3 (5 g, 51% yield) as a yellow solid which was used without further purification.

[0338] Step 2. Preparation of 3-methyl-8-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (4):

[0339]

[0340]Methylamine (6.3 mL, 12.5 mmol) in THF was added to 8-nitro-2-(3-(trifluoromethyl)phenyl)-4H-benzo[d][1,3] In a suspension of a...

Embodiment 2

[0347] Example 2. N-(3-methyl-4-oxo-2-phenyl-3,4-dihydroquinazolin-8-yl)pyridine-3-sulfonamide Synthesis of (Compound 361):

[0348]

[0349] Pyridine-3-sulfonyl chloride hydrochloride 7 (280 mg, 1.3 mmol) was added to 8-amino-3-methyl-2-(3-(trifluoromethyl)phenyl)quinazoline-4(3H)- Ketone 5 (100 mg, 0.313 mmol) in pyridine (5 mL). The reaction mixture was heated at 80°C for 12 hours. Pyridine was removed in vacuo. The residue was dissolved in CH 2 Cl 2 , with saturated NaHCO 3 Washed with aqueous solution, dried (MgSO 4 ) and concentrate. The crude residue was purified by MPLC with CH 2 Cl 2 / MeOH (0-10%) elution followed by CH 3 CN was recrystallized to give compound 361 (77 mg, 53% yield). MS(ESI) calculated value C 21 h 15 f 3 N 4 o 3 S: 460.08; found value: 461 [M+H].

Embodiment 3

[0350] Example 3. N-(4-oxo-2-(3-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-8-yl)pyridine-2- Synthesis of formamide (compound 231):

[0351] Step 1. Preparation of 8-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (8):

[0352]

[0353] 8-nitro-2-(3-(trifluoromethyl)phenyl)-4H-benzo[d][1,3] Azin-4-one 3 (150 mg, 0.45 mmol) was added to a solution of ammonia (5.0 mL, 10 mmol) in IPA. The reaction mixture was heated at gentle reflux for 12 hours and then cooled to room temperature. Pour the reaction mixture into H 2 O, the resulting precipitate was collected by filtration and washed with H 2 O washed and dried in vacuo. The crude residue was recrystallized from EtOAc to afford 8 (91 mg, 62% yield) as a yellow solid.

[0354] Step 2. Preparation of 8-amino-2-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (9):

[0355]

[0356] Compound 9 was prepared in 99% yield by a method analogous to the preparation of 8-amino-3-methyl-2-(3-(trifluoromethyl)phenyl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel sirtuin-modulating compounds, corresponding pharmaceutical compositions comprising a sirtuin-modulating compound, alone and / or in combination with another therapeutic agent, and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Description

[0001] References to related applications [0002] This application claims the benefit of US Provisional Application No. 61 / 194,576, filed September 29, 2008, the contents of which are incorporated herein by reference. Background technique [0003] The Silent Information Regulator (SIR) family of genes represents a highly conserved group of genes present in the genomes of organisms ranging from archaebacteria to eukaryotes. The encoded SIR proteins are involved in various programs ranging from the regulation of gene silencing to DNA repair. Proteins encoded by members of the SIR gene family show a high degree of sequence conservation in the 250 amino acid core domain. A well-characterized gene in this family is S. cerevisiae SIR2, which involves a silent HM locus containing information specifying yeast mating type, telomere position effects, and cellular aging. The yeast Sir2 protein belongs to the family of histone deacetylases. The Sir2 homologue (CobB), in Salmonella typ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/12A61K31/5377C07D405/12A61K31/4375A61P3/10C07D413/12A61K31/439A61P5/50C07D417/12A61K31/4709C07D239/91C07D417/14A61K31/497C07D401/14C07D453/02A61K31/506C07D403/12A61K31/517C07D403/14
CPCC07D311/30C07D405/12C07D405/14C07D417/12C07D417/14A61K31/353A61K31/4025A61K31/4155A61K31/422A61K31/427A61K31/4433A61K31/4439A61K31/497A61K31/506A61K31/5377A61K45/06A61P1/04A61P1/16A61P3/00A61P3/04A61P3/06A61P3/10A61P5/50A61P9/00A61P9/04A61P9/10A61P9/12A61P11/00A61P13/08A61P13/12A61P15/00A61P15/08A61P19/02A61P19/06A61P19/10A61P25/00A61P25/28A61P27/02A61P35/00A61P43/00A61K2300/00C07D311/22
Inventor 奇·B·武克里斯托弗·奥尔曼罗伯特·B·珀尼布赖恩·怀特
Owner SIRTRIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com